Blood test may spot lung cancer recurrence months before scans

NCT ID NCT07257471

First seen Jan 09, 2026 · Last updated May 08, 2026 · Updated 15 times

Summary

This study looks at whether measuring certain DNA markers (SHOX2 and PTGER4) in the blood can detect leftover cancer cells after a minimally invasive treatment called co-ablation for early-stage lung cancer. About 30 adults with non-small cell lung cancer who cannot have surgery will give blood samples before treatment and up to 2 years after. The goal is to see if these markers can predict recurrence earlier than standard scans, helping doctors tailor follow-up care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Haidian Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100080, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.